November 04, 2020: “Sobi announced the commercial launch of Doptelet® (avatrombopag) in Europe, with the United Kingdom as the first country for launch. Doptelet is a thrombopoietin receptor agonist (TPO-RA) approved for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
Patients with CLD typically require one to three invasive diagnostic and therapeutic procedures per year, and each of these procedures carries a risk of bleeding.
Thrombocytopenia, if not effectively treated, can lead to serious uncontrolled bleeding, resulting in prolonged hospitalisations and other post-procedure complications.
Doptelet mimics the biological effects of thrombopoietin (TPO) in stimulating the development and maturation of megakaryocytes, resulting in increased platelet counts.
In ADAPT-1 and ADAPT-2, two global phase 3 clinical studies in adult patients with severe thrombocytopenia and CLD, Doptelet was shown to effectively increase platelet counts and reduce both platelet transfusions and rescue procedures for bleeding when undergoing invasive procedures.
“The launch of Doptelet offers an additional treatment option for patients living with CLD,” said Sofiane Fahmy, Head of Europe at Sobi.
“Since the acquisition of Dova Pharmaceuticals, our focus has been on expanding sustainable patient access to Doptelet from the US to Europe.
We are delighted that Doptelet is now available in the UK for this initial indication, and we look forward to continue rolling out Doptelet in other European markets.”
As a part of the Sobi’s commitment to haematology treatments, the roll out of Doptelet in the EU will continue to bring Doptelet to new markets and new indications subject to regulatory approval.”
https://www.sobi.com/en/press-releases/sobi-launch-dopteletr-avatrombopag-europe-1861948
